The Pros and Cons of a Single ‘Euro—Price’ For Drugs Adrian Towse Current Opinion 18 October 2012 Pages: 271 - 276
The Role of Cost—Consequence Analysis in Healthcare Decision—Making Josephine A. MauskopfJohn E. PaulAndy Stergachis Leading Article 18 October 2012 Pages: 277 - 288
Applications of Modelling Studies Mark J. C. NuijtenJohn Starzewski Leading Article 18 October 2012 Pages: 289 - 291
The Selection of Data Sources For Use in Modelling Studies Mark J. C. Nuijten Review Article 18 October 2012 Pages: 305 - 316
A Short Term Cost-Effectiveness Model For Oral Antidiabetic Medicines in Europe Sheila C. HoodLieven AnnemansMaureen Rutten-van Mölken Original Research Article 18 October 2012 Pages: 317 - 326
Average Annual Drug Cost and its Determinants in a Population Based Cohort of HIV—Positive Adult Men and Women Aslam H. AnisRobert S. HoggMartin T. Schechter Original Research Article 18 October 2012 Pages: 327 - 336
Cost-Effectiveness Analysis of Early Lisinopril Use in Patients With Acute Myocardial Infarction Maria Grazia FranzosiAldo Pietro MaggioniEmanuele Cavalieri Original Research Article 18 October 2012 Pages: 337 - 346
Economic Evaluation of Insulin Lispro versus Neutral (Regular) Insulin Therapy Using a Willingness—To—Pay Approach Peter DaveyDavid GraingerMatthew Dobson Original Research Article 18 October 2012 Pages: 347 - 358
Meropenem Stephen M. HollidayPaul Benfield Adis Pharmacoeconomic Drug Evaluation 18 October 2012 Pages: 359 - 377